Several gaps remain in understanding the “elimination” of lymphatic filariasis and identifying the most efficient strategies to help countries achieve this target. The following issues have been prioritized:
- evaluating new combinations of quality-assured essential medicines for use in MDA and frequencies of distribution, which are more effective than and as safe as current regimens;
- modelling potential new MDA regimens to estimate long-term efficacy and number of rounds required to meet elimination targets;
- developing new programmatic tools to plan, implement and monitor distribution of preventive chemotherapy for the purpose of enhancing coverage of MDA;
- devising standardized, cost–effective strategies for post-elimination surveillance including new diagnostic tests to measure infection and exposure in both humans and vectors;
- formulating efficient strategies to quantify the number of lymphoedema and hydrocele patients at subnational level;
- developing new medicines or treatment regimens to reverse or stop progression of clinical disease;
- advocating sustained MDA and MMDP in countries where these interventions are already being implemented and starting them in countries where they have not yet been introduced.
You are watching: "Lymphatic Filariasis Elimination Program: Alleviating Suffering, Ending Shame"
The Carter Center
Learn about the disease
In order to view files in .wmv format, you will need Windows Media Player 9, Streaming mode. Multimedia help
+41 22 791 1637
+41 79 540 50 86 (mobile)